This site is intended for healthcare professionals

In an interim analysis Opdivo in CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells.- BMS

Read time: 1 mins
Last updated:28th Sep 2020
Published:26th Sep 2020
Condition: Bladder Cancer
Type: drug
Register free for full access to